<DOC>
	<DOCNO>NCT00893971</DOCNO>
	<brief_summary>The purpose study evaluate safety single dose PT003 compare single dos PT001 PT005 , compare PT001 plus PT005 deliver together two separate single dos healthy subject .</brief_summary>
	<brief_title>Study Evaluate Single Inhaled Doses PT001 , PT003 , PT005 PT001 Plus PT005 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Provide sign write inform consent 1855 year age Healthy subject confirm medical history , physical examination , vital sign , pulmonary function test , electrocardiogram clinical laboratory test Female subject childbearing potential sexually active must willing undergo pregnancy test agree use two form contraception Body mass index ( BMI ) 18.5 30 , inclusive Nonsmokers least 6 month prior screen Pulmonary function test within normal limit Willing remain study center least 1224 hour test day Venous access arm allow collection numerous blood sample Women pregnant lactate Clinically significant medical condition Viral illness within last 30 day Symptomatic prostatic hypertrophy bladder neck obstruction Known narrowangle glaucoma History bowel obstruction Clinically significant abnormal electrocardiogram Positive Hepatitis B surface antigen positive Hepatitis C antibody Positive screen test HIV antibodies History hypersensitivity beta2agonists , anticholinergic , component MDI Known suspect history alcohol drug abuse within last 2years Greater normal alcohol consumption Ingestion poppy seed within 48 hour prior screen Ingestion poppy seed within 48 hour prior , alcohol , xanthine grapefruitcontaining food beverage within 24 hour prior , , confinement Positive breath alcohol result Positive urine drug screen Use beta2agonists , anticholinergic prior recruitment interview Lower respiratory tract infection require antibiotic previous 6 week Use prescription medication Use counter product , herbal product , diet aid , hormone supplement Donation &gt; 450 ml blood within 8 week first treatment dose Clinically significant vital sign abnormality Clinically significant biochemical , hematological urinalysis abnormality Affiliations investigator site Treatment investigational study drug participation another clinical trial study within last 30 day 5 half life prior screen , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>